Summit Therapeutics Inc. (SMMT) shares rose 4.0% to $14.16 as of September 2, 2026, a moderate gain from the prior close of $13.62. BestStocks flagged the session as a major change for SMMT. The move is tied to price move up. Below, we break down what changed for SMMT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
SMMT climbed 4.0% to $14.16
Summit Therapeutics rose 6.5% on August 26, 2026, driven by positive Phase III clinical trial results for ivonescimab in biliary tract cancer and a Bernstein analyst upgrade. The HARMONi-GI1 study met its primary overall survival endpoint, reinforcing confidence in the bispecific antibody's efficacy across multiple solid tumor indications.
What it means for Summit Therapeutics Inc. investors
For Summit Therapeutics Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 4.0% session move. Weighing against that: Summit Therapeutics Inc. moved -10.08% intraday from $14.98 to $13.47; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $23.65, implying +67.0% upside from $14.16. Over the past 90 days analysts logged 2 upgrades and 0 downgrades. BestStocks rates the overall signal quality low (52/100). With earnings roughly 47 days out, the next report is the most likely near-term test of the move.
SMMT price reaction
SMMT last traded at $14.16, up $0.54 (+3.96%) from the previous close of $13.62. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $12.43 and $15.12, and it currently sits about 64% of the way up that band.
Bullish and bearish analyst opinions on Summit Therapeutics Inc. (SMMT)
The consensus analyst price target on Summit Therapeutics Inc. (SMMT) is $23.65, 67.0% above the recent $14.16. Over the past 90 days analysts logged 2 upgrades, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on SMMT line up.
▲ The bullish case
+Wall Street's consensus price target of $23.65 implies +67.0% upside from $14.16.
+The Street's most bullish target is $38.00 (+168.4%).
+2 analyst upgrades in the past 90 days, most recently Bernstein to Market Perform (2026-08-25).
+Material positive event.
+Positive 4.0% session move.
▼ The bearish case
−The most bearish analyst target is $11.90 (-16.0%).
−Summit Therapeutics Inc. moved -10.08% intraday from $14.98 to $13.47.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 2, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Summit Therapeutics Inc. (SMMT) moved -2.97% from $14.15 to $13.73 on 2026-08-28. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting no unusual trading activity.
Summit Therapeutics rose 11.53% to $14.90 following a Bernstein analyst upgrade and positive momentum around its ivonescimab program. According to the web catalyst, the upgrade boosted near-term sentiment, while recent Phase III HARMOni trial data publications in *The Lancet Oncology* regarding the bispecific antibody continue to attract investor attention.
Material / Earnings2026-08-26+6.5%
Summit Therapeutics Inc. (SMMT) moved -3.53% from $14.75 to $14.23 on August 26, 2026, despite positive Phase 3 clinical trial results announced that day. Partner Akeso reported that the HARMONi-GI1 study met its primary overall survival endpoint for ivonescimab plus chemotherapy in first-line advanced biliary tract cancer, demonstrating statistically significant survival superiority over AstraZeneca's durvalumab plus chemotherapy. Bernstein also issued a positive target price upgrade.
Material / Earnings2026-08-24-3.3%
Summit Therapeutics Inc. (SMMT) moved -2.68% from $13.08 to $12.73 on 2026-08-24. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Material / Earnings2026-08-21+5.9%
Summit Therapeutics Inc. (SMMT) moved +3.62% from $12.70 to $13.16 on 2026-08-21. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move occurred on volume near its 5-day average.
Summit Therapeutics (SMMT) fell 4.93% to $13.31 on August 14, 2026, driven by a combination of a wider-than-expected Q2 net loss ($0.28 per share versus $0.26 consensus), recent institutional share offloading by major holders such as Dimensional Fund Advisors, and persistent investor caution over overall survival data requirements for its lead cancer drug ivonescimab (per finance.yahoo.com). Volume elevated at 2.81x the historical average for this time of session.
Material / Earnings2026-08-13-7.3%
Summit Therapeutics Inc. (SMMT) moved -7.35% from $15.11 to $14.00 on 2026-08-13. We checked news, earnings, analyst updates, filings, and corporate actions. While no single discrete catalyst was identified, the decline occurs amid ongoing investor re-evaluation of ivonescimab's clinical data maturity, regulatory timeline, and recent cautious analyst sentiment including price target trims from Wall Street firms. Volume was 1.9x the 5-day average—modestly elevated.
Material / Earnings2026-08-10+6.5%
Summit Therapeutics Inc. (SMMT) moved +5.20% from $14.13 to $14.87 on 2026-08-10. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average at 1.1x.
In-depth SMMT event analyses
Permanent, dated analyses of SMMT's most significant sessions.
Why did Summit Therapeutics Inc. (SMMT) stock move?
Summit Therapeutics rose 6.5% on August 26, 2026, driven by positive Phase III clinical trial results for ivonescimab in biliary tract cancer and a Bernstein analyst upgrade. The HARMONi-GI1 study met its primary overall survival endpoint, reinforcing confidence in the bispecific antibody's efficacy across multiple solid tumor indications.
How much did SMMT stock rise?
SMMT gained 3.96% ($0.54) versus the prior close of $13.62, last trading at $14.16 on 0.8× average volume.
When is Summit Therapeutics Inc.'s next earnings date?
SMMT's next earnings report is estimated for 2026-10-19 — about 47 days away.
What is the analyst price target for SMMT?
The consensus analyst price target for SMMT is $23.65, about 67.0% above the current $14.16. Over the past 90 days, analysts recorded 2 upgrades, 4 maintains, and 0 downgrades.
How BestStocks tracks SMMT
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for SMMT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 2, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
